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 Pilot Study to Test Outcome Questions for the WOMAN-2 trial of tranexamic 
acid for the prevention of postpartum haemorrhage 
 
Protocol 
 
STUDY OVERVIEW  
This protocol describes a pilot study to test a draft questionnaire for a subset of secondary outcomes 
in the future WOMAN-2 Trial. The WOMAN-2 Trial is a randomised, double blind, placebo-controlled 
phase III clinical trial testing the effects of giving Tranexamic acid (TXA) to women with anaemia who 
have just given birth vaginally in Africa and Asia. The primary outcome of the WOMAN-2 trial is 
postpartum haemorrhage. Secondary outcomes will include a clinical outcomes as well as a series of 
participant reported outcomes related to maternal health and wellbeing. To ensure the suitability of 
the questions used to measure the participant reported outcomes, it is necessary to pilot test them 
in advance of their use in the WOMAN-2 Trial.   
 
The value of conducting this pilot study is to ensure that the questions included in the participant 
reported outcomes questionnaire will be effective at answering the relevant trial research questions. 
This pilot study intends to verify that each question is clear, understood by participants in the same 
way the trial team understands them, culturally appropriate, translated correctly, and is able to 
measure what it intends to measure.  
 
This pilot study will be conducted in a selection of hospitals which will be conducting the WOMAN-2 
Trial in Nigeria, Pakistan, and Uganda. The pilot study population will include participants similar to 
those to be included in the WOMAN-2 Trial: women who are anaemic, and having given birth. 
Participantswill take part in one interview which includes answering questions from the draft 
participant reported outcomes questionnaire. A small subset of participants enrolled in this pilot 
study will also take part in a cognitive interview directly following the questionnaire to learn how 
they understood the questions.   
 
Overall aim of project 
To pilot test the suitability of the draft participant reported outcomes questionnaire intended to be 
used within the WOMAN-2 Trial.  
 
Specific objectives of project 
 Assess whether items would address the relevant aspects of outcomes and experiences  
 How is each question understood by participants?  
 Does the research team understand each question in the same manner?  
 Are the translations of each question accurate and appropriate? 
 Are the questions, answer choices, and directions clear to respondents? 
 How differently do participants with different birth outcomes answer the questions?  
METHODOLOGY 
 
The draft questionnaire will be developed and “outcomes” questions will be informed by a literature 
review focusing on the impact of anaemia on physical, emotional and mental well-being. The draft 
questionnaire will be refined through discussions with obstetricians and women with different 
birthing experiences. The final draft questionnaire will then be translated in collaboration with 
partnering sites in Nigeria, Pakistan, and Uganda. A selection of WOMAN-2 Trial sites will be used to 
pilot the questionnaire. Anaemic women at the selected sites who plan to give vaginal birth or who 
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have recently given birth with be approached and asked to participate in this pilot study to help test 
these draft questions, which will take place as one interview. The interview will be conducted just 
before women are discharged from the hospital or anytime up to 42 days after giving birth. 
Administration of the pilot questionnaire is expected to take about 15-30 minutes. A short 
demographics form will be completed to document key health and birth information about each 
woman. A range of women with different birth outcomes will be included to understand how 
women with different birth experiences, in the various settings, react to and answer questions.  
 
A small subset of respondents will also be asked to participate in a cognitive interview directly 
following administration of the questionnaire. This will include asking participants how they 
understood the questions, their thoughts as they listened to and answered the questions, their 
opinions about questions and the answer response choices, and any other thoughts they would like 
to share about the questionnaire. Cognitive interviews are expected to take about 30 minutes. Voice 
recording for a selection of the interviews will be done where participants have given consent for 
this. 
 
All potential participants will be provided with both written and verbal information about the study. 
They will be reassured that participation is totally voluntary and non-participation will not impact 
their care in anyway. Also, they will be informed that they can withdraw at any time. Those women 
who are willing to participate will be asked to provide written informed consent. In the event a 
woman cannot read or write, her consent will be independently witnessed.  
 
Much of the information gathered from the pilot study will be analysed in real time as this pilot is 
intended to be a dynamic study, changing as results are understood. For example, if after the first 
several interviews it is evident that one question is not understood well by participants, it will be 
revised and the new question will be included.  
 
The number of participants to be enrolled for this studywill be dynamic and will depend on how 
women answer draft questions and what types of issues are identified during the pilot. Enrolment is 
expected to be between around 30-300 women. 
 
Results from the pilot will be analysed quantitatively and qualitatively. Quantitative analysis will 
examine which answer choices are selected or not selected, ceiling or floor effects, and if different 
birth experiences result in different answer choices selection.  Qualitative analysis will include 
examining how respondents understood the questions, and suggestions for improvement in 
questions, answer choices, wording, and translations.  Results of the analysis will inform the design 
of the final questionnaire to be included in the WOMAN-2 Trial.  
 
Participant responses to the draft questionnaire will be captured on the draft questionnaire form. 
Information about each participant’s health and birth status will be documented on a demographics 
form. For those women participating in cognitive interviews, results will be documented on a 
cognitive interview capture formand voice recordings made for a selection of interviews. Voice 
recordings may be transcribed and translated. Data will be entered into a database in London at the 
Clinical Trials Unit (CTU). Data will be analysed in real time, and also after the study is completed. 
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Questionnaire Topics 
 
Physical State& Symptoms of Anaemia 
 Ability to perform activities 
 Pain 
 Fatigue 
 Energy level 
 Dizziness 
 Headache 
 Strange or fast beating heart 
 Shortness of breath 
 
Feeling state 
 Sad 
 Confused/forgetful 
 Frustration 
 Difficulty concentrating 
 
Exercise ability 
 Pre & Post breathlessness test 
 6 minute exercise test 
 
Opinions on how questions were asked 
 Visual analogue scales – different methods  
 Understanding of questions 
 Suggestions for improving questions 
CONFIDENTIALITY AND DATA STORAGE 
 
 
Each woman will be given an identification number for her study participation. The study 
identification number will be written on the study forms (demographics, pilot questionnaire, and 
cognitive interview capture form). The consent form will contain the participant’s full name. A link 
log will be used to link each participant’s name to her participant identification number.   
 
Data captured on forms and audio recordings will be stored securely in locked cabinets at the 
participating hospitals. Data will also be stored at the CTU in London in locked cabinets and in a 
password-protected database. Once the pilot study is completed, the data will become a part of the 
WOMAN-2 Trial documentation, and will be subject to the data storageprocedures for the WOMAN-
2 Trial.  
RISKS 
 
Women who agree to enrol in this pilot study will be agreeing to answer a questionnaire soon after 
giving birth. Women who have recently given birth will be tired and recovering.  Answering a 
questionnaire might be uncomfortable. This questionnaire will also be asking women about their 
mood, feelings, and physical abilities in light of just having given birth. This might highlight feelings of 
sadness or concern for some women. The physical process of answering the questions might also 
contribute to a woman’s physical or mental tiredness. 
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If a woman is feeling too tired or uncomfortable to answer the questions in the pilot study, she can 
stop at any time. She will be told this at consent and before starting the questionnaire. Staff 
administering the questionnaire will be trained to be sensitive to each woman’s needs, look for signs 
of discomfort, and how to respond in those situations.  Written into the pilot questionnaire are 
check points to ask if the respondent is willing to continue.  If a woman is particularly upset, 
triggered, or would like psychological support, with her permission, her doctor will be asked to 
arrange appropriate care or referral.  
BENEFITS 
 
There may not be a direct benefit to women who participate in this study. Women may be pleased 
that they are able to contribute to improving the quality of a future study which will look at whether 
tranexamic acid prevents postpartum haemorrhage and improves maternal health and wellbeing 
outcomes.  
PROJECT TIMELINE 
 
Pilot testingwill begin in Pakistan once LSHTM and the local Pakistan site Ethics Committees give a 
favourable opinion. Nigeria will be the second country to begin pilot testing, followed by Uganda. 
Exact timelines depend on the local ethics committee review cycles. The pilot is expected to start as 
early as the end of March or April 2018. The pilot is expected to last from one to several months, and 
this will depend on how women respond to questions. This pilot study will be conducted while other 
preparations from the WOMAN-2 Trial are ongoing. 
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